Stoke Therapeutics financials
$25.88+1.49%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.3M | $6.2M | $1.4M | $10.6M | $13.8M | $158.6M | $22.6M | $4.9M | $4.8M | $4.2M | $2.8M | $3.3M |
| Gross profit | $9.3M | $6.2M | $1.4M | $10.6M | $13.8M | $158.6M | $22.6M | $4.9M | $4.8M | $4.2M | $2.8M | $3.3M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$65.4M | -$53.4M | -$61.4M | -$43.1M | -$27.3M | $111.2M | -$13.7M | -$30.0M | -$29.3M | -$28.4M | -$29.6M | -$27.2M |
| Net income | -$61.6M | -$50.0M | -$57.9M | -$38.3M | -$23.5M | $112.9M | -$10.5M | -$26.4M | -$25.7M | -$26.4M | -$27.0M | -$24.5M |
| Net margin | −660.8% | −802.7% | −4132.2% | −360.7% | −170.0% | 71.2% | −46.4% | −540.0% | −531.9% | −625.6% | −962.1% | −741.9% |
| Diluted EPS | $-0.93 | $-0.79 | $-0.96 | $-0.65 | $-0.40 | $1.90 | $-0.18 | $-0.47 | $-0.46 | $-0.57 | $-0.60 | $-0.55 |
| EBITDA | -$65.4M | -$53.0M | -$61.0M | -$42.6M | -$27.3M | $111.7M | -$13.1M | -$29.5M | -$28.8M | -$27.8M | -$29.0M | -$26.6M |
| Operating cash flow | $0.00 | -$60.6M | -$30.5M | -$30.4M | $0.00 | $131.8M | -$23.2M | -$21.6M | -$17.5M | -$24.6M | -$20.6M | -$17.3M |
| Free cash flow | $0.00 | -$60.9M | -$30.7M | -$30.5M | $0.00 | $131.7M | -$23.2M | -$21.7M | -$17.5M | -$24.6M | -$20.9M | -$17.6M |
| Diluted shares | 66.0M | 63.1M | 60.5M | 58.6M | 58.4M | 59.4M | 57.7M | 56.3M | 55.8M | 46.2M | 45.0M | 44.3M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $110.0M | $155.7M | $84.2M | $83.4M | $101.5M | $274.8M |
| Short-term investments | $182.8M | $187.9M | $200.4M | $164.9M | $146.2M | $82.5M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $394.0M | $443.3M | $418.4M | $360.3M | $384.5M | $406.9M |
| Total liabilities | $48.4M | $48.4M | $66.0M | $52.2M | $49.6M | $56.8M |
| Shareholders' equity | $345.5M | $394.9M | $352.5M | $308.1M | $334.9M | $350.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology